Lindsey Trickett
Investor Relations Contact bij F-STAR THERAPEUTICS, INC.
Profiel
Lindsey Trickett is currently the Vice President of Investor Relations at Prelude Therapeutics, Inc. and the VP of Investor Relations & Communications at F-star Therapeutics, Inc. She previously worked as the Vice President of Investor Relations at Intellia Therapeutics, Inc. Ms. Trickett received an undergraduate degree from the University of Kentucky and an MBA from Georgetown University.
Actieve functies van Lindsey Trickett
| Bedrijven | Functie | Begin |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Investor Relations Contact | - |
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | - |
Eerdere bekende functies van Lindsey Trickett
| Bedrijven | Functie | Einde |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Investor Relations Contact | - |
Opleiding van Lindsey Trickett
| University of Kentucky | Undergraduate Degree |
| Georgetown University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
